40-50% response rate for brigatinib after other next-gen ALK inhibitors
Crizotinib was the first drug licensed to treat ALK-positive non-small cell lung cancer (ALK+ NSCLC). Since then, a range of next-generation ALK-inhibitors including ceritinib, alectinib, and brigatinib have earned FDA approval ...
May 31, 2019
0
1